Company
Almatica
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
11
10 still marketed
Novel approvals
0
Approvals since 2021
9
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Duloxetine Hydrochloride approved Feb 27, 2026
- Escitalopram approved Aug 29, 2025
- Zolpidem Tartrate approved May 9, 2023
- Venlafaxine Besylate approved Jun 29, 2022
- Venlafaxine Besylate approved Jun 29, 2022
- Citalopram Hydrobromide approved Jan 31, 2022
- Sertraline Hydrochloride approved Oct 4, 2021
- Sertraline Hydrochloride approved Oct 4, 2021
- Loreev Xr approved Aug 27, 2021
- Gralise approved OrphanJan 28, 2011
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (10)
Newest FDA action first.
- Sertraline Hydrochloride Sertraline Hydrochloride · 2021
- Duloxetine Hydrochloride Duloxetine Hydrochloride · 2026
- Escitalopram Escitalopram Oxalate · 2025
- Gralise Gabapentin · 2011
- Venlafaxine Besylate Venlafaxine Besylate · 2022
- Citalopram Hydrobromide Citalopram Hydrobromide · 2022
- Zolpidem Tartrate Zolpidem Tartrate · 2023
- Macrobid Nitrofurantoin, Nitrofurantoin, Macrocrystalline · 1991
- Loreev Xr Lorazepam · 2021
- Zestoretic Hydrochlorothiazide, Lisinopril · 1989
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.